Akero Therapeutics Inc [AKRO] stock was sold by Cheng Andrew at the price of US$0.36 million

In a filing, Akero Therapeutics Inc revealed its President and CEO Cheng Andrew unloaded Company’s shares for reported $0.36 million on Jun 18 ’25. In the deal valued at $54.84 per share,6,620 shares were sold. As a result of this transaction, Cheng Andrew now holds 549,867 shares worth roughly $29.34 million.

Then, Gangloff Scott A. sold 848 shares, generating $46,504 in total proceeds. Upon selling the shares at $54.84, the Chief Technology Officer now owns 23,452 shares.

Before that, Lamy Patrick sold 875 shares. Akero Therapeutics Inc shares valued at $47,766 were divested by the Senior VP, Commercial Strategy at a price of $54.59 per share. As a result of the transaction, Lamy Patrick now holds 31,698 shares, worth roughly $1.69 million.

BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.

Price Performance Review of AKRO

On Monday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock fall -5.04% to $53.36. Over the last five days, the stock has lost -1.24%. Akero Therapeutics Inc shares have risen nearly 132.71% since the year began. Nevertheless, the stocks have risen 91.80% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $21.02 was recorded on 01/14/25.

Levels Of Support And Resistance For AKRO Stock

The 24-hour chart illustrates a support level at 52.11, which if violated will result in even more drops to 50.86. On the upside, there is a resistance level at 55.56. A further resistance level may holdings at 57.76.

How much short interest is there in Akero Therapeutics Inc?

A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-06-13, growing by 1.45 million shares to a total of 7.75 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 6.3 million shares. There was a rise of 18.76%, which implies that there is a positive sentiment for the stock.

The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.